|
|
Post by cannon5974 on Jun 27, 2014 14:46:41 GMT -5
approval looks as expected....I'm shocked this is tanking so bad
|
|
|
|
Post by bradleysbest on Jun 27, 2014 14:48:03 GMT -5
Why the HUGE drop then!
|
|
|
|
Post by kc on Jun 27, 2014 14:49:14 GMT -5
Not sure... bother's me as I purchased more as it was rebounding from 9.50 to 9.75.... Oh well. I know it will be back. Not today but in a couple of week.s
|
|
|
|
Post by jpg on Jun 27, 2014 14:54:55 GMT -5
The shorts are taking advantage of every situation where we do not have complete information to scare investors. Once situational awareness is regained this should stop. They knew the 'sell the news' will happen. Not certain who really is selling though?
|
|
|
|
Post by BD on Jun 27, 2014 14:57:54 GMT -5
Geez, bizarre scenario to wake my phone up to after a flight. This is good, right? LOL
|
|
|
|
Post by liane on Jun 27, 2014 14:59:43 GMT -5
Geez, bizarre scenario to wake my phone up to after a flight. This is good, right? LOL Yes it's good. Just very unexpected with no halt. |
|
|
|
Post by milachka63 on Jun 27, 2014 15:08:38 GMT -5
Options are totally whacked! Managed to sell some Jul 10 puts when MNKD dropped below 9.  |
|
|
|
Post by seanismorris on Jun 27, 2014 15:09:08 GMT -5
FDA approves Afrezza
Friday, June 27, 3:58 PM ET | MNKD
MannKind's (MNKD -6.1%) long regulatory journey is finally over as the FDA approves Afrezza, a fast-acting inhalable prandial insulin. Its main value proposition is that patients do not have to time their dose at a particular point before a meal in order to synchronize the insulin's effect with the spike in food-related glucose. They simply inhale the insulin at the beginning of the meal or within 20 after starting the meal thereby minimizing the potential for a hypoglycemic event caused by the mistiming of the prandial insulin dose.
The product has a Boxed Warning advising that bronchospasm has been observed in patients with asthma and chronic obstructive pulmonary disease. Afrezza is contraindicated for patients with chronic lung disease.
The regulatory approval has a RIMS (Risk Evaluation and Mitigation Strategy) attached that includes a communication plan to inform healthcare professionals about the risks of acute bronchospasm in patients with chronic lung disease.
The FDA's clearance also requires four Phase 4 clinical trials to evaluate Afrezza's pharmacokinetics, safety and efficacy in pediatric patients, to evaluate the potential risk of pulmonary malignancy with Afrezza and two pharmacokinetic-pharmacodynamic euglycemic glucose-clamp trials to characterize dose-response and within-subject variability.
|
|
|
|
Post by otherottawaguy on Jun 27, 2014 15:11:20 GMT -5
|
|
|
|
Post by BD on Jun 27, 2014 15:33:32 GMT -5
Well, couldn't do any trading while traipsing through Dulles Airport. Nice to see the PPS leveling back off. It's awesome to think that the shorts' game plans for a mid-July approval are out the window. I know it isn't likely, but boy would I love to see a partnership announcement before Monday,,,  |
|
|
|
Post by esstan2001 on Jun 27, 2014 15:44:09 GMT -5
Congrats to all that held! Happy it came early and when unexpected. Less anticipatory ogeda. Monday will be interesting. Have to read the full label, waiting for the Mannkind official pr.
|
|
|
|
Post by biotec on Jun 27, 2014 15:47:09 GMT -5
Well, couldn't do any trading while traipsing through Dulles Airport. Nice to see the PPS leveling back off. It's awesome to think that the shorts' game plans for a mid-July approval are out the window. I know it isn't likely, but boy would I love to see a partnership announcement before Monday,,, Or Buyout news, Im sure greenhill is busy this weekend. |
|
|
|
Post by lynn on Jun 27, 2014 15:52:15 GMT -5
Omg !! I went to the gym thinking how boring these past cpl trading days have been , looking at the ticker in my car while I was driving there ,) , well that just made my day !!!!! & year !! As I'm sure all of yours as well I still can't figure out the drop but I obviously have some catching up to do ! I may have to place a limit BUY order for Monday as I have to work ./ Have a great weekend you all !!! Cheers Wow !!! |
|
|
|
Post by seanismorris on Jun 27, 2014 15:53:34 GMT -5
FYI
Insulin causing hypos isn't news.
You might find shorts pushing this, but Afrezza is about causing significantly less hypos (than other insulin) and less side effects than other available treatments.
As for MNKD volatility, WOW Day's Range: 8.20 - 11.11
I think you just saw the shorts getting out with their money made. The fact that MNKD closed at 10$ and is up after hours is bullish.
I don't think the shorts (risk/reward wise) want to stick around for the partnership announcement.
Time for some Al partnership magic. We should take a poll for that..my guess two weeks.
|
|
|
|
Post by mannkind111 on Jun 27, 2014 16:07:25 GMT -5
Im kinda glad I stayed out of this. Too much volatility. I was hoping to buy in next week, but man....
|
|
